Single-dose pharmacokinetics of the new immunosuppressant RS-61443 in the rabbit
Related Experiment Videos
R W Yatscoff1, R Keenan, D F LeGatt
1Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
Abstract:
The pharmacokinetics of mycophenolic acid (MPA) were investigated in six New Zealand white rabbits following (i.v.) and (s.c.) administration of RS-61443. Plasma concentrations of MPA were analyzed by high-performance liquid chromatography (HPLC). Model-dependent and -independent parameters were calculated. Mycophenolic acid is rapidly cleared with a terminal half-life of approximately 1.0 h. The volume of distribution subsequent to i.v. administration indicates minimal distribution into tissues. The mean residence time and volume of distribution were greater for the s.c. as compared to the i.v. route of administration. The insignificant difference in the area under the curve between the two dosage routes infers that the bioavailability of RS-61443-derived MPA by the former route of administration is comparable to the latter. Trough concentrations at the doses administered are below the detection limit of the HPLC procedure. The implications of these findings in relation to the therapeutic monitoring of the drug are discussed.
Insights
This study on RS-61443 in rabbits shows mycophenolic acid (MPA) has rapid clearance and comparable bioavailability via intravenous and subcutaneous routes. Therapeutic drug monitoring implications are discussed.
Area of Science:
- Pharmacology
- Drug Metabolism and Pharmacokinetics
Background:
- Mycophenolic acid (MPA) is an immunosuppressant drug.
- Understanding its pharmacokinetic profile is crucial for effective therapeutic monitoring.
Purpose of the Study:
- To investigate the pharmacokinetics of MPA following intravenous (i.v.) and subcutaneous (s.c.) administration of RS-61443 in New Zealand white rabbits.
- To compare the bioavailability and pharmacokinetic parameters between the two routes.
Main Methods:
- Six New Zealand white rabbits were administered RS-61443 via i.v. and s.c. routes.
- Plasma MPA concentrations were quantified using high-performance liquid chromatography (HPLC).
- Model-dependent and -independent pharmacokinetic parameters were calculated.
Main Results:
- MPA exhibited rapid clearance with a terminal half-life of approximately 1.0 hour.
- Volume of distribution was minimal after i.v. administration, suggesting limited tissue distribution.
- Bioavailability via the s.c. route was comparable to the i.v. route, with no significant difference in the area under the curve.
- Mean residence time and volume of distribution were higher for the s.c. route compared to i.v.
Conclusions:
- RS-61443 demonstrates comparable bioavailability between i.v. and s.c. administration in rabbits.
- The rapid clearance and limited distribution of MPA have implications for therapeutic drug monitoring strategies.
- Further research may be needed to optimize dosing and monitoring for clinical application.